Comparison of plasma methylated SEPT9 screening marker in both left- and right-sided colon cancer to GFOBT and CEA results
K Tóth, A Kalmár, VÁ Patai, A Schöller, K Leiszter, G Valcz, B Wichmann, F Sipos, R Stöhr, H Golcher, V Schellerer, Z Nagy, B Barták, B Molnár, Z Tulassay · Zeitschrift für Gastroenterologie · 2012 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background: Methylated SEPT9 (mSEPT9) DNA was found as a sensitive and specific biomarker for colorectal cancer (CRC) from peripheral blood. Many aspects of the biology of mSEPT9 in the plasma of CRC patients have already been explored, including relationship to CRC location, guaiac-based faecal occult blood test (gFOBT) positivity and other blood-based tumor markers. Aims: 1, Determine the sensitivity of mSEPT9 for CRC detection in the left- and right-sided CRC. 2, Compare mSEPT9 and gFOBT positivity rates in individuals with no evidence of disease (NED) and CRC patients. 3, Compare mSEPT9 and another blood-bas…
